Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

VANGUARD has selected five companies for up to $200,000 in non-dilutive funding contracts and 10 companies for the 2025 ...

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

[1] Revenues of $5.1 million fell 32% from $7.5 million due to a decrease in activity related to the Biomedical Advanced ...

WHO has recognised mental health and, more recently, brain health as public health priorities.1 This momentum was further advanced at the National, Regional and International Plans for Brain and ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

It ain’t what you don’t know that gets you into trouble. It’s what you know for sure that just ain’t so.” Mark Twain’s quip ...

Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ worth of mRNA research ...

(Reuters) -Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage ...

Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork), a ...

Trump officials are capitalizing on lingering COVID resentment to undermine American vaccine policy.